Related Experiment Video
Updated: Feb 7, 2026
CIRCLE-Seq for Interrogation of Off-Target Gene Editing
Published on: November 1, 2024
Colchicine for epidermolysis bullosa acquisita
B B Cunningham1, T T Kirchmann, D Woodley
1Department of Dermatology, Stanford University Medical School, Palo Alto, California, USA.
Background:
Epidermolysis bullosa acquisita (EBA) is a chronic subepidermal blistering disease that is difficult to treat. Recently one patient with severe EBA was described who responded dramatically to colchicine.
Objective:
Our purpose was to determine the efficacy of colchicine in the treatment of EBA.
Methods:
Four patients with severe EBA refractory to conventional therapy were treated with colchicine 0.6 to 1.5 mg a day for up to 4 years.
Results:
In all four patients the lessening of skin fragility and the decrease in spontaneous blister formation were dramatic; few side effects were noted.
Conclusion:
Colchicine should be considered in the treatment of EBA.
More Related Videos
09:40Identification of a Murine Erythroblast Subpopulation Enriched in Enucleating Events by Multi-spectral Imaging Flow Cytometry
Published on: June 6, 2014
13:59Studying Mitotic Checkpoint by Illustrating Dynamic Kinetochore Protein Behavior and Chromosome Motion in Living Drosophila Syncytial Embryos
Published on: June 14, 2012